Imatinib (Gleevec®, (Figure 1)), a diarylamide-4-(pyridin-3-yl)pyrimidine conjugate, is the first FDA-approved BCR-ABL inhibitor for the treatment of CML patients.3 Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.